ArticleVeterinary world2025
Therapeutic efficacy of
Article in Veterinary world, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Subclinical mastitis (SCM) in dairy cattle significantly compromises milk quality, animal health, and farm profitability, often remaining undetected due to the absence of clinical signs. The increasing antimicrobial resistance associated with conventional treatments highlights the need for effective alternatives. This study aimed to evaluate the therapeutic potential of Materials and Methods: Fifteen California mastitis test-positive cows were randomly divided into three groups (n = 5/group). Group A received tylosin (18 mg/kg intramuscular), Group B received CA (120 g orally), and Group C received both treatments. Milk samples were analyzed pre- and post-treatment for somatic cell count (SCC), pH, electrical conductivity, fat, protein, lactose, and solids-not-fat (SNF) content. Hematological parameters, including red blood cell (RBC), white blood cell, hemoglobin, packed cell volume (PCV), and lymphocyte percentages, were evaluated alongside oxidative stress markers - total antioxidant capacity (TAC) and total oxidative stress (TOS). Results: Significant post-treatment reductions in SCC, pH, and conductivity were observed in all groups. Group C exhibited the most pronounced improvements in lactose, fat, and SNF, with no change in protein. Group B demonstrated the highest TAC increase and TOS reduction, affirming CA's antioxidative potential. Hematological evaluations revealed systemic improvements post-treatment, particularly in RBC and PCV levels. Group B also showed increased lymphocyte counts, further indicating immunomodulatory effects. Conclusion: CA exhibits considerable therapeutic potential in managing SCM, especially when combined with tylosin. Its antioxidative and immunomodulatory effects may enhance udder health and milk quality while reducing reliance on antibiotics. Future large-scale studies are warranted to confirm these findings and explore CA's integration into sustainable mastitis management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.